TCF7 and acute lymphoblastic leukemia: Given the high frequency of co-occurring mutations with NRAS (OR 5.833, p value 0.0067, Supplementary Data 9) and association with NRAS signaling (Fig. 2j) we sought to investigate whether the TCF7-SPI1 fusion cooperates with oncogenic NRAS to drive T-ALL.